Dear Reader,

See this drop of liquid?

Scientists the world over are calling this liquid a “revolution in cancer therapy.” 

They say it’s the “dawn of a new era” in cancer treatment. 

That’s because this drop of liquid is on the verge of changing what happens when someone is diagnosed with cancer. 

You see, there are a total of 200 different types of cancers known to mankind – Pancreatic Cancer…Breast Cancer…Lung Cancer…Prostate Cancer...you name it.

And when a person is unfortunate enough to be diagnosed with one of these cancers, they usually begin a round of chemotherapy.

But there’s a big problem with chemotherapy, or “chemical” therapy - 

It doesn’t just kill the cancer cells - it also kills healthy cells. 

That’s why the side effects are just awful.

But what makes this new drug so powerful is that it’s able to attack cancer cells and leave the healthy ones alone.

If that sounds like science fiction, consider this –  

The largest drug companies are scambling to invest billions of dollars into this new "Smart Chemo."

The list goes on and on…  

Never has medical science moved into a new technology so quickly.   

The Journal Nature calls it “The Dawn of a New Era.”

And Morgan Stanley says it “Could Transform Cancer Care.” 

Yet, that’s just scratching the surface.

But big business isn't the only one getting in on the act.

As the power of this breakthrough comes into focus, it’s become more than just a matter of public health…

It’s about leading the field of medicine for the next 50 years to come.

That’s one reason Congress passed bill HR 6638 – which includes more than $50 billion in funding for cancer research.

This treatment will not just change medicine...   

It has the potential to eliminate side effects from cancer treatment. 

Its current market cap is only $363 million.

But Morgan Stanley believes it will grow into a $140 billion market.

That's because it reminds me of our last “Smart Chemo” play, Immunogen. 

On July 6, 2022, we recommended Immunogen at $5.30 per share.

Just eighteen months later, the company was taken over by Abbvie at $31.26 per share.

A 430% gain is great... 

...but the gain could have been 1,000% or more if the company wasn't taken over.

In a moment, I’ll share what I know about “Smart Chemo” and why it's revolutionizing cancer treatment. 

Most importantly, I’ll explain how you can personally profit from it.  

In fact, if our numbers are correct, and this imitates the success of Immunogen, you could potentially see life-changing profits.   

Once you see how this technology works, you’ll understand why people, companies and governments around the world are rushing to get in on it.    

But first, it’s important for you to know who I am and why I am so confident about this unique opportunity. 

My name is Dylan Jovine.

I started my career on Wall Street in 1991.

But I didn’t start at an “establishment” firm like Goldman Sachs or J.P. Morgan. I grew up poor and went to city college. No big Wall Street firm would hire me. I was too much of an outsider.

Thankfully, I got my big break from another Wall Street “outsider” – Peter Jacquith.

He’s one of the bankers who became famous for saving New York City from bankruptcy in the 1970’s. He started a boutique firm after leaving Lazard Freres’ & Company.

It was an opportunity I would not take for granted. I may not have had the connections other people had.

But nobody was going to work harder than I did.

I managed accounts. But I fell in love with researching stocks.

Studying a stock was like reading a short history book about the town the company was in, the people that worked there and the products they made. I loved it. I couldn’t believe people got paid to do this.

Within three years, I earned a reputation for picking stocks right before they were taken over. Here are some of the biggest and most exceptional winners I picked early on in my career.

Stocks like Paramount which was bought out by Viacom three months after I recommended it for a 100% gain.

Or the 70% gains over four months we made when US Reinsurance was taken over after I recommended it.

Or the 78% gains in four months we booked when Chase Manhattan Bank was acquired by Chemical Bank.

Remember, this is the early 1990’s - before the internet bull market of the 1990’s. And here I am, this 23-year-old kid picking takeover after takeover. 

And sure, not every pick was a winner. But in 1996 it was enough for my clients to bankroll me to start my own brokerage firm. 

And that’s how, at just 24 years old, I became one of the youngest people in American history to launch a start a registered broker-dealer and market maker.

 Our offices were at 100 Wall Street, to the right....

Because of what I accomplished at such a young age Wall Street took notice.  

But it wasn’t until I predicted the 2008-09 financial crisis and crash a year before it happened that the general public took notice.

Then I was invited onto places like Fox Business News to share my opinion. 

My message was simple:

The stock market at 6,500 is like walking into your car dealership when everything is on sale marked 90% off!  

Some of the best companies on earth were being sold at “fire sale” prices – and it seemed like the rest of the world was too afraid to buy them. 

Check out a few of the biggest winners we booked after the crash - 

Like the 646% returns we booked after buying American Express at $14.24 a share and selling for over $90 just four years later.

Or the 700% in profits with Starbucks which I bought at $8 in January 2010 which then soared to a high of $56 in January 2015.

Or the 459% profits we found buying shares of AutoNation between $10 - $11 a share in 2009 and selling for over $63 in 2015.

Or the 235% gains that came after we bought FactSet Research at $63.23 in 2009 and sold for over $200 in 2018.

Or John Harland, which was taken over six months after I recommended it, giving us a 35% gain.

Or shares of K-Swiss, which saw a 65% gain between 2004 and 2005 after we recommended it.

And remember Radio Shack? We recommended it in 2007 and it saw 80% gains over the next six months from $16 to $29.

Or the 40% gains we earned over four months when Hilton Hotels was taken private.

Now I don’t say all this up to brag. That’s not my style. 

I say it to show you that folks who’ve been following my advice over the past thirty years have had the opportunity to make some good money. I know what I’m doing.

And yet - as great as all these gains were, I fully believe the opportunity in this little drop of liquid is fundamentally different.   

It’s one of those “once-in-a-generation” kind of opportunities…giving you the chance to earn "once-in-a-generation" profits.

And that brings us to today.   

So how does a guy who built his reputation on takeover targets get involved in biotechs?  

Right around the time I turned 40, I was diagnosed with metabolic syndrome. At first, I was shocked. But then I looked in the mirror and I didn’t recognize the face that looked back at me.   

Gone was the young man beaming with energy. In his place stood a man pushing 300 lbs with bags under his eyes who had not had a good night sleep in five years.   

My wife had just given birth to my first-born daughter Lila and a second one was on the way.   

Close to thirty years working 12-hours a day, 7 days a week had taken their toll.   

On one hand, I had started, built and sold two separate investment-related companies before I had turned 40: the brokerage firm, which I had sold in 2000, and Tycoon Research.   

On the other hand, I was slowly killing myself.   

I think we all get to an age when we learn were not playing with house money. Well, that’s the day I learned I wasn’t.   

So in 2013, I sold my last business and decided to take some time off. Get healthy again. 

People said I retired.  But once an investor, always an investor.   

Only now, because of my health problems, I turned my attention to investing in drug and healthcare companies.   

So, I’ve spent the past decade studying the biggest breakthroughs in medicine. 

And in 2018, I launched Behind the Markets to share some of that research with other independent investors.  This way, folks know exactly what to buy, when to buy and when to sell.

But first let me explain why this opportunity is so unique…and why both big business and government are rushing to seize the opportunity.    

It’s because this opportunity reminds me of one of our biggest winners: Immunogen. 

Folks who invested in Immunogen at $5.30 per share had the opportunity to ride it to Abbvie’s $31.26 per share takeover price. 

That’s a 430% win.

And this could happen as quickly as Immunogen was taken over.  

Because of the unique, high-stakes power of this treatment, Big Pharma is rushing to get their hands on these drugs. It’s like a biotech gold rush. 

That’s why 87 new “Smart Chemo” drugs have entered development in the past two years alone. 

And large biopharma companies are going all-in on “Smart Chemo”;

In that way it’s become like the Space Race – only this time, the winner could forever change the way we treat cancer.  

And because of that we think one of two things happens - it either rockets higher on its own or it’s taken over by a Big Pharma giant, much like Immunogen was. 

I know that’s a big claim.   

And it should give you pause.    

But if you were told just ten years ago that you’d be carrying a device in your pocket as powerful as your home computer, you’d think it was science fiction.   

Yet that’s why smart investors are putting more than just their money into this…

That's why Bill Gates said in an interview with Business Insider that “cancer won’t be a problem in 30 years.”

He's just one of many savvy investors who know how unique this opportunity is.

A typical FDA clinical trial has 3 Phases. 

Phase 1 is a test for safety and dosing.

In this phase, scientists aren’t really testing to see if the drug works. They’re testing to see if there are any adverse side effects. 

They do this by using a small group of between 20 and 80 people. 

The good news is that roughly 63.2% of all drugs make it out of Phase 1. 

The bad news is that I call this the “stock promoter phase”… 

That’s because the small biotech’s that tend to run up in Phase 1 often do so because of good public relations as much as anything. 

Phase 2 expands the test. 

Phase 2 tests can include hundreds of people. 

While safety and dosing are being evaluated, it’s really the first time that scientists are looking to see if the drug actually works. 

And that’s what makes Phase 2 very risky: only 30% of drugs make it out of Phase 2 and onto Phase 3.

The final phase Phase 3. 

Phase 3 tests can include thousands of people. 

In addition to side effects, the big focus of Phase 3 is to see how well the drug works at different dosing regimens. 

Find a company with a safe drug that can impact a massive market that’s in Phase 3 trials – and generational wealth can be made. 

That’s where we’ve had most of our success. 

Just like the “Smart Chemo” drugs that I’ve been talking about. 

That’s why I’ve spent four weeks in front of my computer rushing to get this out to you. This innovative company looks ready to take off, and I want you to have the opportunity to make life-changing gains.  

Understanding this very simple diagram is what has allowed me to spot ChemoCentryx as it was moving from Phase 2 to Phase 3…delivering gains of 435%

The same thing happened with Krystal Biotech. A lot of folks got in too early and rode the ups and downs for years. But we recommended it when it crossed from Phase 2 to Phase 3, delivering gains of 275%.

Same for Kura Oncology. When that stock entered Phase 3 trials, I recommended shares which delivered gains of 124%.

And it happened recently with Immunogen. We recommended shares at $5.30 – right before the company won FDA approval for their “Smart Chemo” drug Elehare, and they got taken over by Abbvie for 430% gains.

Of course, the key is to know when a drug is going from Phase 2 to Phase 3 – or when it seems likely to move from Phase 3 to FDA approval. That’s why I wake up at 4am most mornings to do my research and read more by noon than most people do all week.

What makes this treatment so unique is that it could change what it means to have cancer.

I’ve never been more certain of anything in almost thirty years as a professional investor.   

So what is this breakthrough that’s could revolutionize cancer treatment?  

How on earth does a new drug have the potential to eliminate the side effects of chemo that people have been suffering from for generations?  

In short, it’s a treatment that’s on the verge of forever changing chemo as we currently know it.   

They’re called Antibody Drug Conjugates, or “ADCs” for short. 

Let me explain....

If “Smart Chemo” was just invented for ovarian cancer alone, the opportunity would be sweet. 

Folks who invested in Immunogen at $5.30 saw a 430% gain on their money after Abbvie agreed to buy them for $31.26 per share. 

Not a bad gain in under a year. 

But this opportunity is different. Frankly, it’s just bigger. An order of magnitude bigger.     

What sets it apart is that it’s not about developing one drug that treats just one type of cancer.     

That means the diseases you can use this approach with are so far without limitless.

What it did for breast cancer it could do for any other cancer. 

Cancers like… 

Some of the worst side effects of cancer treatment could become a thing of the past…

Future generations would learn about them by reading about them in the history books.   

The implications of this is mind-boggling…

The New York Times reports it’s, “more effective and less toxic than many existing treatments.”

The Breast Cancer Research Foundation said it, “significantly reduced patients’ risk of death.”

If all of this sounds like something out of a SCI-FI movie consider this...  

The Wall Street Journal reported that Smart Chemo “cut the rate of death in women with a type of advanced breast cancer by one-third.”… 

So, breast cancer is still far from cured…

Yet, one third is a really big deal. 

That could mean 27,100 more women will survive each year!

Which is why the Food and Drug Administration approved it last August, four months ahead of schedule. 

And yet, this is only the beginning…   

Every industry is starting to implement this new technology… as a recent edition The Wall Street Journal said best when they called Smart Chemo, “big pharma’s secret weapon.”

With the stakes so high you can bet Big Pharma will keep their eyes on this company as more of their hotly anticipated results come in. 

Either way, we're at the very beginning of this revolution.

And this is just the beginning of what looks to be a very profitable ride for early investors.   

The market for this treatment will grow beyond anything we’re used to.   

“Smart Chemo” is to chemotherapy what the iPhone was to the old cell phone: fasten your seatbelt because things are about to change very quickly.

Right now, only the savviest scientists and investors seem to know about it. But that’s starting to change.   

If you were to make only one investment in the next decade, this is it. It doesn’t get clearer than this. 

Of that I have no doubt.  

Here are the details…  

As I mentioned, “Smart Chemo” is poised to radically change how we treat cancer.   

And the best way to capitalize on this opportunity is to invest in one of the small companies at the forefront of this technology. 

Let’s take another look at Immunogen.

What made Immunogen such a huge winner for us was that it was early in the race to develop “Smart Chemo” for ovarian cancer patients. 

And their stock was stuck between $4 and $7 a share for months, as most of Wall Street didn’t put 2+2 together yet. 

But we did. We saw the opportunity before the rest of the crowd. 

And as I mentioned a few minutes ago, early investors saw a 430% gain on shares after we recommended it.     

I am confident investors with the foresight to invest in the right companies during the “Smart Chemo” revolution could be rewarded with similar returns. 

But this could happen sooner.  

Remember, we were early with “Smart Chemo”…

We held Immunogen for almost two years before shares skyrocketed. 

But now the “cat is out of the bag” – and Wall Street is waking up to the big opportunity in front of us.  

That’s why I don’t even think the company will stay independent for long. The technology is too valuable to Big Pharma. 

You see, you can have the best drugs in the world but if you don’t know how to sell them, nobody will ever hear about them.

That’s where Big Pharma comes in. They have the marketing muscle to turn a great new drug into a legitimate blockbuster. 

Think about it…

On Sept 15th, 2023, the National Center for Biotechnology Information said, “this class of biopharmaceutical drugs has revolutionized treatment”  

On September 2017, 2023, the peer reviewed journal, The Atlas of Genetics and Cytogenetics in Oncology and Haematology, said that Smart Chemo is a “revolution in cancer therapy.”  

There’s no way Big Pharma is going to let those huge paydays go to small biotech companies which are often more like independent R & D labs than actual businesses selling drugs to a global market. 

That makes this small biotech a prime takeover candidate.

Small biotech’s become very attractive takeover targets when their drug could completely change the way we treat cancer. 

Below are three biotech takeovers I picked since 2018  -

Array Biopharma jumped 148% in one day when Pfizer bought them because of their new cancer drugs…

When it looked like Tesaro’s new drugs were going to be covered by Medicare, Glaxo bought the company, handing investors 91% profits in one morning.

And Loxo Oncology jumped 71% in one morning after Eli Lilly bought the company.

But here’s the thing…  

That’s why I don’t often recommend the Big Pharma giants. 

Folks who follow my research know I prefer recommending biotech’s on the very forefront of this massive change. The biotech’s that the large companies are partnering with.   

That’s where all the innovation is. And that comes in the form of smaller companies with the world’s leading scientists.   

My research has led me to a firm that has the patent on a “Smart Chemo” drug that recently won an FDA approval on their lymphoma drug. 

And they have the two other key ingredients: a strategic partner and they’re at the forefront of this medical revolution. 

In the last few months, they’ve announced positive results from a partnership with IGM Biosciences and Sobi, one of the largest biotech companies in the world. 

Both companies would be natural acquirers.    

And even if a small part of the $140 billion market flows toward this small cap firm, the growth will be through the roof.   

Immunogen rang up 430% gains after their ovarian cancer drug won FDA approval.

That’s why this small company reminds me so much of Immunogen.   

To give you an edge, I’ve put all the details in a special report called “Smart Chemo - The Small Biotech Revolutionizing Cancer Treatment.”

Again, the “Smart Chemo” revolution is in its infancy. Most people I talk to have never even heard of it - yet. 

Which is why the smart money is pouring so much into this idea. By the time your neighbor is talking about it, it’s going to be too late.

So even if this handles just one disease, like Immunogen, you can see its stock rise 430%.  

And this is the company best position to capture the bulk of the upside.    

I have no doubt, if you invest in this company today, you give yourself the opportunity to make the kind of money that lets you put your name on a building.   

There is no time to waste. 

The biggest obstacle stopping the stock from becoming a 1,000% winner is that it gets taken over by Big Pharma, just like Immunogen was. 

But that still put 430% gains in the pockets of the investors who bought shares after we recommended it. 

I detail all of this information in our brand-new report, “Smart Chemo - The Small Biotech Revolutionizing Cancer Treatment.”

And the report is yours – absolutely free as a bonus when you join our exclusive VIP investing service, Behind the Markets.

If you join us, I want you to have this report for free because there doesn’t seem to be anyone else putting together this information. 

You see, the world is on the cusp of a medical revolution. New treatments promise to revolutionize how we treat the diseases that kill so many people each year. 

And I’ve made it my mission to do the research and share all my best work with my subscribers. 

But nobody else seems to be talking about this.

It’s almost surreal. I feel the same way I did before the housing market crashed.

I began warning folks on May 12, 2006, almost two years before the market crashed.

My first target was Wachovia Bank. The stock was selling at $55.82.

Within two years the stock collapsed to $5.54 a share, a loss of over 90%.

And that was just the tip of the iceberg.

On June 9, 2006, I warned customers that the entire stock market was going to drop.

At the time I wrote -

A year later, the Dow Jones Industrial Average began to drop 45%.

The S & P 500 dropped 47%...

And the Nasdaq Composite dropped 54%...

My point is, I have a proven history of being ahead of the crowd.

That’s why I had to tell this story. I think this is the most exciting moment in the history of medicine and I get to share it with you!

That’s exactly why I worked hard to get you this valuable report, “Smart Chemo - The Small Biotech Revolutionizing Cancer Treatment.”

I’ve put this new report together for members of my exclusive VIP service, Behind the Markets.

We hunt for drugs with blockbuster potential at Behind the Markets.

The focus of this unique service is simple: we hunt for small, little-known stocks at the forefront of massive changes.

Stocks that are so far ahead of their competitors, they can change a market….

Stocks with lower share prices…small market capitalizations…and rapidly growing revenue…

Stocks that we think smart investors should know about. 

Stocks that could change your life.

As soon as you become a member of Behind the Markets, you become part of my “inner circle” – just like my mother – and you’ll get access to every single investment opportunity I discover each month.

As a member of Behind the Markets, you’ll receive:

But most importantly, once you join Behind the Markets you get access to yours truly – me.

And the truth is that I love what I do... 

I love that I get the opportunity to share it with you…

That’s why I work so hard at my job…and why I try so hard to do right by our subscribers. 

From now on you’ll know about the big warnings like this before the general public catches wind of them – just like my friends and family. 

You’ll also get timely buy and sell signals, just like my readers did after the market crashed in 2009.

I want to educate so folks can position themselves for the dangerous world that we now find ourselves in.  

Helping investors protect their wealth and seize big opportunities is my mission.

In short, you get to access a brain that has picked some exceptional winners during the past three decades.

This is why I’ve kept the cost of Behind the Markets at the lowest possible level.

Just $49.

And frankly, I believe it’s a steal at that price.

“Smart Chemo - The Small Biotech Revolutionizing Cancer Treatment,” will be sold for more than that on our website just on its own. 

I’ve studied this issue for years and I’ve had my research and writing staff putting together this report for weeks just to get it to you.

This report hand-delivers four companies we believe are well-positioned to grow from the coming revolution in cancer treatment. 

I don’t know about you, but I’ve been around long enough to know how rare that is.

But look - as I mentioned earlier, this is about feeding more than my wallet. It’s about feeding my soul. And the best way for me to do that is to help as many people as I can.

And I grew up on welfare and food stamps. So, I will never forget the value of a dollar.